Biotech Values

[rwwine]

"Many investors remain unconvinced that NVS/MNTA will receive FDA approval for generic Copaxone before Teva’s patents expire in 2014; for those investors, the patent case is mostly academic."

On the MNTA board....I expressed my views. Specifically thinking MNTA would recieve approval from the FDA by the end of 2011. In your view....do you think I'm too optimistic?

TIA